| This week's sponsor is Premier Research. | |  | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Tuesday, June 12, 2018 Eli Lilly and AstraZeneca have pulled the plug on two phase 3 trials of BACE inhibitor lanabecestat in Alzheimer’s disease. The partners stopped the studies after an independent interim analysis deemed they were destined to fail. |
|
|
| This week's sponsor is Catalent. | |  | |
Top Stories Tuesday, June 12, 2018 Off-target, or unintended, editing is a key safety concern of CRISPR-Cas9, as it can lead to cancer. Two new studies show that CRISPR editing could raise the risk of targeted cells—those being edited to treat disease—developing tumors. Tuesday, June 12, 2018 Targovax has hit pause on its neoantigen vaccine R&D strategy after seeing independent data that will redefine the standard of care in resected pancreatic cancer. The leap forward in the treatment of the disease forced Targovax to rethink its strategy and pull out of a planned phase 2 trial. Monday, June 11, 2018 Juvenescence, an anti-aging startup based in the British Isles, reeled in a $50 million series A, which will allow it to push forward on its "core projects" and ramp up licensing deals and partnerships. Tuesday, June 12, 2018 Galmed Pharmaceuticals unveiled top-line results from a yearlong phase 2b study of its oral treatment for nonalcoholic steatohepatitis, demonstrating a statistically significant reduction in liver fat without worsening fibrosis. Tuesday, June 12, 2018 Like just about all its peers in the pharma sector, Roche has been trying to find ways to reduce the costs of R&D—but CEO Severin Schwann won’t contemplate doing so by consolidating its Swiss-led research operations with those of subsidiary Genentech. Tuesday, June 12, 2018 Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis. | This week's sponsor is cobra:bio. | |  | Accelerating Protein Production Since 1995
Cobra’s maxXpress service uses UCOE technology enables rapid production of monoclonal antibodies (mAbs), recombinant proteins and biosimilars while ensuring efficient, stable expression. More... |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
